KZR Insider Trading

Insider Ownership Percentage: 9.30%
Insider Buying (Last 12 Months): $0.00
Insider Selling (Last 12 Months): $3,874.40

Kezar Life Sciences Insider Trading History Chart

This chart shows the insider buying and selling history at Kezar Life Sciences by year and by quarter.

Skip ChartChart Data in Insider Trading History Table
2022202320242025$0bought$0soldQ2Q3Q4Q1Q2Q3Q4Q1Q2Q3Q4Q1Q2-$1M$0$1MTotal Insider BuyingTotal Insider Selling

Kezar Life Sciences Share Price & Price History

Current Price: $4.60
Price Change: Price Increase of +0.09 (2.00%)
As of 04/2/2025 05:00 PM ET

This chart shows the closing price history over time for KZR up to the past year.

Skip Chart and Table DataPrice Data in Insider Trading History Table
Days: 30 | 90 | 365
MayJunJulAugSepOctNovDecJanFebMar$4.51Closing price on 04/01/25:

SEC Filings (Institutional Ownership Changes) for Kezar Life Sciences (NASDAQ:KZR)

67.90% of Kezar Life Sciences stock is owned by institutions. Institutional ownership can be a sign of analyst confidence in the fundamentals of the stock.

Institutional Buying and Selling by Quarter

This chart shows the instiutional buying and selling at KZR by year and by quarter.

Skip Institutional Buying and Selling Chart and Table DataRead Chart Data in Institutional Trading History Table
2022202320242025$1.26Mbought$102MsoldQ2Q3Q4Q1Q2Q3Q4Q1Q2Q3Q4Q1-$100M-$50M$0$50M$100MTotal InflowsTotal Outflows
Kezar Life Sciences logo
Kezar Life Sciences, Inc., a clinical-stage biotechnology company, engages in the discovery and development of novel small molecule therapeutics to treat unmet needs in immune-mediated diseases and cancer in the United States. The company's lead product candidate is zetomipzomib (KZR-616), a selective immunoproteasome inhibitor that is in Phase 2b clinical trials for various indications, including lupus nephritis, dermatomyositis, and polymyositis; Phase 1b clinical trials in systemic lupus erythematosus; and completed Phase 2a clinical trials in lupus nephritis. Its preclinical products include KZR-261, a novel first-in-class protein secretion inhibitor for the treatment of tumors resistant to traditional chemotherapeutics. Kezar Life Sciences, Inc. was incorporated in 2015 and is headquartered in South San Francisco, California.
Read More on Kezar Life Sciences

Today's Range

Now: $4.60
Low: $4.51
High: $4.70

50 Day Range

MA: $5.94
Low: $4.51
High: $6.48

52 Week Range

Now: $4.60
Low: $4.36
High: $9.18

Volume

8,665 shs

Average Volume

30,680 shs

Market Capitalization

$33.61 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.49

Who are the company insiders with the largest holdings of Kezar Life Sciences?

Kezar Life Sciences' top insider shareholders include:
  1. Mark C Schiller (Insider)
Learn More about top insider investors at Kezar Life Sciences.